Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval
Source: SeekingAlpha
2026-03-11 02:46:47 ET
Article Thesis
I wrote about Aquestive Therapeutics, Inc. ( AQST ) at the beginning of May last year, and I saw it as a “Buy” with the stock around $3. My thesis is underpinned by Anaphylm , their epinephrine-based sublingual film, which was in an advanced FDA approval phase. Epinephrine is the first-line treatment to stop a potentially life-threatening allergic reaction, and Anaphylm’s perceived advantage is especially its ease of transport, for example, on the back of a mobile phone....
Read the full article on Seeking Alpha
For further details see:
Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval
Aquestive Therapeutics Inc.
NASDAQ: AQST
AQST Trading
1.47% G/L:
$4.13 Last:
919,131 Volume:
$4.06 Open:
AQST Latest News
March 30, 2026 07:00:00 am
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm(TM) (dibutepinephrine) Sublingual Film
March 26, 2026 09:00:00 am
AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt
AQST Stock Data
$477,556,785
111,815,853
0.67%
63
N/A
Pharmaceuticals
Healthcare
US
Warren
